ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting

ANI’s Phase 4 trial met efficacy endpoints but safety risks remain significant.

What the company is saying

ANI Pharmaceuticals highlights statistically significant efficacy results from the SYNCHRONICITY Phase 4 trial of its fluocinolone acetonide intravitreal implant for chronic NIU-PS, emphasizing improvements in visual acuity and retinal thickness at 6 months. The company frames the data as supportive of the implant’s use in steroid-responsive patients, with both 6- and 24-month outcomes presented at a major ophthalmology conference. Executive commentary from Nikhil Lalwani, President and CEO, stresses the value of these results for retina specialists considering ILUVIEN. Principal Investigator Dr. David R.P. Almeida underscores the durability of efficacy and a safety profile consistent with prior trials. The announcement foregrounds efficacy and inflammation control, while also providing a detailed breakdown of adverse events. The tone is confident, focusing on clinical impact and regulatory progress, with only minimal forward-looking language about ongoing data generation.

What the data suggests

The SYNCHRONICITY trial enrolled 108 patients, with a mean age of 64 and 65% female. At 6 months, the mean best corrected visual acuity (BCVA) improved by 3.6 letters (baseline 62.5 to 65.8, p=0.0077), and mean central subfield thickness (CST) decreased by 157.5 microns (baseline 505.7 to 348.2, p<0.0001), meeting both co-primary endpoints. Over 24 months, 79.6% of study eyes had no recurrence of non-infectious inflammation, while 20.4% experienced recurrence with a median time to recurrence of 168 days. Resolution of macular edema was achieved in 48.2% of study eyes at month 24. Vascular leakage dropped from 78.7% at baseline to 55.6% at month 24. Adverse events were frequent: 29% experienced treatment-related events, with ocular hypertension in 6%, cataract in 5%, and reduced visual acuity in 5%. Intraocular pressure (IOP) of ≥25 mmHg occurred in 17.6%, and ≥35 mmHg in 4.6%; 29.6% used IOP-lowering medication and 7.4% required surgical or laser intervention. Cataract surgery was performed in 14.8% of study eyes. The safety profile is consistent with prior trials, which showed high rates of cataract (up to 82% in diabetic macular edema and 56% in chronic NIU-PS), IOP elevation, and need for surgical intervention. The data are comprehensive and transparent, but the incidence of adverse events is material.

Analysis

The announcement is a factual and data-rich disclosure of clinical trial results from the SYNCHRONICITY Phase 4 study, with all key claims supported by specific numerical outcomes and statistical significance. Nearly all statements are realised and retrospective, detailing efficacy and safety endpoints at 6 and 24 months, with only a single forward-looking phrase about ongoing commitment to data generation. There is no promotional or exaggerated language, and no claims about future commercial impact, revenue, or profitability. No large capital outlay or long-dated, uncertain returns are referenced. The absence of financial metrics means the signal cannot be strong_positive, but the clinical data is robust and transparent. The tone is proportionate to the evidence, with no narrative inflation.

Risk flags

• ●Ocular adverse events remain a significant risk, with 29% of patients experiencing treatment-related events and 6% developing ocular hypertension. This could limit the implant’s adoption in broader clinical practice, especially in patients at risk for glaucoma or with prior ocular complications.
• ●Intraocular pressure increases were common, with 17.6% of patients experiencing IOP ≥25 mmHg and 4.6% experiencing IOP ≥35 mmHg. Nearly 30% required IOP-lowering medication and 7.4% needed surgical or laser intervention, indicating a substantial management burden and potential for vision-threatening complications.
• ●Cataract formation and surgery are frequent, with 14.8% of study eyes undergoing cataract surgery in the 24-month period. This aligns with prior trial data showing cataract rates as high as 82% in some populations, raising concerns about long-term visual outcomes and patient quality of life.

Bottom line

ANI Pharmaceuticals’ SYNCHRONICITY Phase 4 trial for its fluocinolone acetonide intravitreal implant in chronic NIU-PS met both efficacy endpoints, showing statistically significant improvements in visual acuity and retinal thickness at 6 months, with durable inflammation control in nearly 80% of eyes over 24 months. However, the safety profile is challenging: almost a third of patients experienced treatment-related adverse events, and a notable proportion required intervention for elevated intraocular pressure or cataract. These risks are consistent with prior corticosteroid implant studies and may constrain the product’s uptake in routine practice. The results are credible and data-rich, but the high rate of ocular complications means that clinical adoption will likely be selective. Investors should focus on future updates regarding commercial uptake, real-world safety, and any new regulatory or reimbursement developments. The most important takeaway is that while efficacy is clear, safety risks will be the key determinant of market success.

Announcement summary

(NASDAQ:ANIP) ANI Pharmaceuticals, Inc. announced that both 6-month and 24-month data from SYNCHRONICITY, its Phase 4, open-label, single-arm clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS), were presented at the American Academy of Ophthalmology (AAO) 2026 Meeting. The SYNCHRONICITY trial met both co-primary endpoints with statistical significance in the intent-to-treat (ITT) population (n=108) at 6 months: mean change from baseline in best corrected visual acuity (BCVA) letter score and mean change from baseline in central subfield thickness (CST). At 6 months, patients had a mean change from baseline BCVA of +3.6 letters gained (p=0.0077), with mean BCVA letter score increasing from 62.5 at baseline to 65.8 at month 6. Mean change from baseline CST at month 6 was -157.5 microns (p<0.0001), with mean CST decreasing from 505.7 microns at baseline to 348.2 microns at month 6. Over the 24-month study period, 86 of 108 study eyes (79.6%) experienced no recurrence of non-infectious inflammation, while 22 study eyes (20.4%) experienced recurrence, with a median time to recurrence of 168 days. The proportion of study eyes with resolution of macular edema was 48.2% (52/108) at month 24. The proportion of study eyes with vascular leakage decreased from 78.7% (85/108) at baseline to 55.6% (60/108) at month 24. In the safety population, 29% of patients (31/108) experienced treatment-related treatment-emergent adverse events; the most common were ocular hypertension in 6% (7/108), cataract in 5% (5/108), and visual acuity reduced in 5% (5/108). 17.6% of patients (19/108) experienced intraocular pressure (IOP) of ≥25 mmHg, and 4.6% (5/108) experienced IOP of ≥35 mmHg. IOP-lowering medication was used by 29.6% (32/108), and 7.4% (8/108) required any laser or surgical IOP-lowering intervention. Cataract surgery was reported in 14.8% (16/108) study eyes overall. The study population had a mean age of 64 years, and the majority were female (65%). At baseline, 69% of study patients had a history of ocular surgery prior to enrollment. ILUVIEN is an intravitreal implant designed to release fluocinolone acetonide in the eye for up to 36 months and was approved by the FDA in 2014 for diabetic macular edema and in 2025 for chronic NIU-PS. In diabetic macular edema trials, ocular adverse reactions reported by ≥1% of patients included cataract (82%), myodesopsia (21%), eye pain (15%), conjunctival hemorrhage (13%), posterior capsule opacification (9%), eye irritation (8%), vitreous detachment (7%), conjunctivitis (4%), corneal oedema (4%), foreign body sensation in eyes (3%), eye pruritus (3%), ocular hyperaemia (3%), optic atrophy (2%), ocular discomfort (2%), photophobia (2%), retinal exudates (2%), anterior chamber cell (2%), and eye discharge (2%). Non-ocular adverse reactions reported by ≥5% included anemia (11%), headache (9%), renal failure (9%), and pneumonia (7%). IOP elevation ≥10 mm Hg from baseline at any visit was seen in 34% of ILUVIEN patients versus 10% of sham patients; IOP elevation ≥30 mm Hg was seen in 20% of ILUVIEN patients versus 4% of sham patients. 38% of ILUVIEN patients were treated with IOP-lowering medications versus 14% of sham patients, and 5% of ILUVIEN patients needed surgical intervention for elevated IOP versus 1% of sham patients. The incidence of cataract development in phakic study eyes was 82% in the ILUVIEN group compared with 50% in sham; 80% of ILUVIEN subjects versus 27% of sham subjects underwent cataract surgery, generally within the first 18 months. In chronic NIU-PS trials, ocular adverse reactions reported by ≥1% included cataract (56%), visual acuity reduced (15%), macular edema (11%), uveitis (10%), conjunctival hemorrhage (8%), eye pain (8%), hypotony of eye (7%), anterior chamber inflammation (5%), dry eye (4%), vitreous opacities (4%), conjunctivitis (4%), posterior capsule opacification (4%), ocular hyperemia (4%), vitreous haze (3%), foreign body sensation in eyes (3%), vitritis (3%), vitreous floaters (3%), eye pruritus (3%), conjunctival hyperemia (2%), ocular discomfort (2%), macular fibrosis (2%), glaucoma (2%), photopsia (2%), vitreous hemorrhage (2%), iridocyclitis (1%), eye inflammation (1%), choroiditis (1%), eye irritation (1%), visual field defect (1%), and lacrimation increased (1%). Non-ocular adverse reactions reported by ≥2% included nasopharyngitis (5%), hypertension (3%), and arthralgia (2%). IOP elevation ≥10 mm Hg from baseline at any visit was seen in 22% of fluocinolone acetonide patients versus 12% of sham patients; IOP elevation ≥30 mm Hg was seen in 12% of fluocinolone acetonide patients versus 3% of sham patients. 43% of fluocinolone acetonide patients were treated with IOP-lowering medications versus 41% of sham patients, and 2% of both groups needed surgical intervention for elevated IOP.

Disagree with this article?